U.S SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                               ------------------

                                   FORM 10-QSB

              |X| Quarterly Report Under Section 13 or 15(d) of the
                        Securities Exchange Act of 1934.

                  For the quarterly period ended: June 30, 2002

                           Commission File No. 1-16119
                               ------------------

                             SFBC International Inc.
                             -----------------------
        (Exact name of small business issuer as specified in its charter)


                Delaware                                 59-2407464
                --------                                 ----------
     (State or other jurisdiction of                  (I.R.S. Employer
      incorporation or organization)                  Identification Number)

                              11190 Biscayne Blvd.
                                 Miami, FL 33181
                                 (305) 895-0304
                                 --------------
                          (Address and telephone number
                         of principal executive offices)



State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date:


We had 7,066,752 shares of our common stock outstanding as of August 11, 2002.


Transitional Small Business Disclosure Format (check one):  |_| Yes    |X| No


<PAGE>

<TABLE>
<CAPTION>

                                                              INDEX

                                                                                                                            Page
                                                    PART I - FINANCIAL INFORMATION
<S>            <C>                                                                                                           <C>
ITEM 1.        Financial Statements

               Condensed Consolidated Balance Sheets as of June 30, 2002 (unaudited) and December 31, 2001                   1

               Condensed Consolidated Statements of Earnings for the Three and Six Months Ended June 30, 2002 and 2001       2
               (unaudited)

               Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2002 and 2001             3 - 4
               (unaudited)

               Notes to Unaudited Condensed Consolidated Interim Financial Statements                                      5 - 8

ITEM 2.        Management's Discussion and Analysis of Interim Financial
                   Condition and Results of Operations                                                                     8 - 12

                                                      PART II - OTHER INFORMATION

ITEM 1.        Legal Proceedings                                                                                             12

ITEM 2.        Change in Securities                                                                                          12

ITEM 3.        Defaults upon Senior Securities                                                                               14

ITEM 4.        Submission of Matters to a Vote of Security Holders                                                           14

ITEM 5.        Other Information                                                                                             15

ITEM 6.        Exhibits and Reports on Form 8-K                                                                              15
</TABLE>



<PAGE>


SFBC INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
JUNE 30, 2002 AND DECEMBER 31, 2001
<TABLE>
<CAPTION>

============================================================================================================

ASSETS                                                                            (UNAUDITED)
                                                                                    June 30,      December 31,
                                                                                      2002           2001
                                                                                   -----------   -----------
<S>                                                                                 <C>           <C>
Current Assets
     Cash and cash equivalents                                                     $15,695,933   $39,103,139
     Accounts receivable, net                                                       13,927,695    10,453,729
     Income tax receivable                                                             746,125            --
     Loans receivable from officers/stockholders                                       232,196       363,517
     Prepaids and other current assets                                               5,251,159       289,248
                                                                                   -----------   -----------
          Total current assets                                                      35,853,108    50,209,633

Loans receivable from officers                                                         800,000       800,000

Property and equipment, net                                                         13,872,063     3,928,584

Goodwill, net                                                                       19,808,276     4,483,690

Other intangibles, net                                                               2,878,125       684,973

Deferred income taxes                                                                  672,969            --

Other assets, net                                                                      292,790       376,650
                                                                                   -----------   -----------
          Total assets                                                             $74,177,331   $60,483,530
                                                                                   ===========   ===========


LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities
     Accounts payable                                                              $4,751,641    $1,538,903
     Accrued liabilities                                                            1,602,972     1,318,730
     Advance billings                                                                 765,102     1,483,216
     Income taxes payable                                                                  --     1,046,420
     Deferred income taxes                                                            222,713       222,713
     Notes payable, current portion                                                 1,394,300         7,490
                                                                                   -----------   -----------
          Total current liabilities                                                  8,736,728     5,617,472
Notes payable                                                                        3,045,386         1,248
Deferred income taxes                                                                       --       233,602
Commitments                                                                                 --            --
Stockholders' equity
     Preferred stock. $0.10 par value, 5,000,000 shares authorized, none issued             --            --
     Common stock, $0.001 par value, 20,000,000 shares authorized, 7,173,052 and
        6,670,320 shares issued and outstanding as of June 30, 2002 and
        December 31, 2001                                                                7,173         6,670

Additional paid-in capital                                                          54,708,208    49,913,845
Retained earnings                                                                    7,458,036     4,773,193
Note receivable - officer                                                                   --       (62,500)
Accumulated other comprehensive earnings                                               221,800            --
                                                                                   -----------   -----------
          Total stockholders' equity                                                62,395,216    54,631,208
                                                                                   -----------   -----------
          Total liabilities and stockholders' equity                               $74,177,331   $60,483,530
                                                                                   ===========   ===========
</TABLE>

The accompanying notes are an integral part of these statements.


                                       1
<PAGE>


SFBC INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2002 AND 2001 (UNAUDITED)
<TABLE>
<CAPTION>

================================================================================================================

                                                         Three Months Ended              Six Months Ended
                                                              June 30,                        June 30,
                                                        2002            2001            2002            2001
                                                    ------------    ------------    ------------    ------------
<S>                                                 <C>             <C>             <C>             <C>
Net revenue                                         $ 14,720,863    $  7,571,122    $ 24,303,419    $ 14,153,099
Costs and expenses
     Direct costs                                      8,454,030       4,311,373      13,315,774       8,126,089
     Selling, general and administrative expenses      4,766,890       1,935,081       7,597,955       3,547,128
                                                    ------------    ------------    ------------    ------------
         Total costs and expenses                     13,220,920       6,246,454      20,913,729      11,673,217
         Earnings from operations                      1,499,943       1,324,668       3,389,690       2,479,882
Other income (expense)
     Interest income                                     112,036          88,885         297,296         186,172
     Interest expense                                    (87,022)         (9,599)       (115,554)        (23,267)
                                                    ------------    ------------    ------------    ------------
         Total other income (expense)                     25,014          79,286         181,742         162,905
                                                    ------------    ------------    ------------    ------------
         Earnings before taxes                         1,524,957       1,403,954       3,571,432       2,642,787

Income tax expense                                       169,919         536,000         886,589       1,014,000
                                                    ------------    ------------    ------------    ------------
         Net earnings                               $  1,355,038    $    867,954    $  2,684,843    $  1,628,787
                                                    ============    ============    ============    ============
Earnings per share:
     Basic                                          $       0.19    $       0.24    $       0.39    $       0.45
                                                    ============    ============    ============    ============
     Diluted                                        $       0.18    $       0.19    $       0.36    $       0.40
                                                    ============    ============    ============    ============
Shares used in computing earnings per share:
     Basic
                                                       7,079,480       3,599,815       6,890,302       3,594,785
                                                    ============    ============    ============    ============
     Diluted                                           7,459,428       4,489,414       7,404,560       4,116,236
                                                    ============    ============    ============    ============
</TABLE>


The accompanying notes are an integral part of these statements.


                                       2
<PAGE>


SFBC INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)
FOR THE SIX MONTH PERIODS ENDED JUNE 30, 2002 AND 2001(UNAUDITED)
<TABLE>
<CAPTION>

===================================================================================================================

                                                                                           2002            2001
                                                                                       ------------    ------------
<S>                                                                                       <C>             <C>
Cash flows from operating activities
   Net earnings                                                                           2,684,845       1,628,786
   Adjustments to reconcile net earnings to net cash (used in) provided by operating
   activities:
     Depreciation and amortization                                                        1,024,607         181,549
     Common stock options issued as compensation                                             35,417          85,000
     Common stock issued as compensation                                                         --           5,400
     Changes in assets and liabilities
       Accounts receivable                                                               (1,069,896)       (858,361)
       Income tax receivable                                                               (746,125)             --
       Prepaid expenses and other current assets                                           (695,343)        293,764
       Other assets                                                                        (163,241)        (72,424)
       Accounts payable                                                                     (46,223)       (183,880)
       Accrued liabilities                                                                  (55,826)        342,618
       Advance billings                                                                    (718,114)       (154,096)
       Income taxes payable                                                              (1,046,420)       (126,000)
       Deferred income taxes                                                               (906,571)       (104,000)
                                                                                       ------------    ------------
Total adjustments                                                                        (4,387,735)       (590,430)
                                                                                       ------------    ------------
         Net cash (used in) provided by operating activities                             (1,702,890)      1,038,356
                                                                                       ------------    ------------
Cash flows from investing activities
   Cash consideration - acquisitions, net of cash acquired                              (22,047,577)       (427,567)
   Purchase of property and equipment                                                    (1,229,971)       (946,938)
   Loans to officers/stockholders                                                           131,321              --
                                                                                       ------------    ------------
         Net cash used in investing activities                                          (23,146,227)     (1,374,505)

Cash flows from financing activities
   Net proceeds on notes payable - insurance                                                     --         (94,481)
   Principal payments on notes payable - purchase of assets                                      --         (43,521)
   Principal payments on notes payable - stockholders                                       (62,093)        (93,258)
   Principal payments on notes payable - purchase of company                                     --        (150,000)
   Payments on capital lease obligations                                                         --         (19,615)
   Net (decrease) increase in notes payable - transportation equipment
   Proceeds from the issuance of common stock                                             1,504,004          37,610
                                                                                       ------------    ------------
         Net cash provided by (used in) financing activities                              1,441,911        (363,265)

Net decrease in cash and cash equivalents                                               (23,407,206)       (699,414)

Cash and cash equivalents at beginning of period                                         39,103,139       6,787,603
                                                                                       ------------    ------------
Cash and cash equivalents at end of period                                             $ 15,695,933    $  6,088,189
                                                                                       ============    ============
</TABLE>

                             See accompanying notes.

                                       3
<PAGE>



SFBC INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)
FOR THE SIX MONTH PERIODS ENDED JUNE 30, 2002 AND 2001(UNAUDITED)
<TABLE>
<CAPTION>

=============================================================================================================================

                                                                                                        2002         2001
                                                                                                        ----         ----
<S>                                                                                                  <C>          <C>
Supplemental disclosures:
       Interest paid                                                                                 $   115,554   $   27,767
       Income taxes paid                                                                             $ 2,844,897   $1,244,000
Supplemental disclosures of non-cash investing and finance activities:
       Fair value of net assets (liabilities) assumed in connection with acquisition of businesses   $12,104,260   $  (89,423)
       168,375 shares of common stock issued in connection with acquisition of business              $ 3,255,443   $       --
       Professional fees accrued in connection with acquisition of business                          $   658,362   $   27,324
       Common stock options issued as compensation                                                   $    35,417   $   85,000
       Common stock issued as compensation                                                           $        --   $    5,400
</TABLE>


                             See accompanying notes.



                                       4
<PAGE>



SFBC INTERNATIONAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
================================================================================

--------------------------------------------------------------------------------
NOTE 1.         ORGANIZATION AND BASIS OF PRESENTATION
--------------------------------------------------------------------------------

             Principles of Consolidation and Organization

             The consolidated financial statements include the accounts of SFBC
             International, Inc. and its wholly owned subsidiaries South Florida
             Kinetics, Inc., SFBC Charlotte, Inc., SFBC Ft. Myers, Inc., SFBC
             Canada Inc. which was formed as a wholly-owned Canadian subsidiary
             to acquire 100% of the common stock of Anapharm Inc. on March 18,
             2002 and SFBC Analytical Laboratories Inc. (collectively, the
             "Company"). All significant intercompany balances and transactions
             have been eliminated in consolidation.

             Basis of Presentation

             The accompanying unaudited condensed consolidated financial
             statements have been prepared in accordance with accounting
             principles generally accepted in the United States of America for
             interim financial information and with the instructions to Form
             10-QSB for quarterly reports under section 13 of the Securities
             Exchange Act of 1934. Accordingly, they do not include all of the
             information and footnotes required by accounting principles
             generally accepted in the United States of America for complete
             financial statements. In the opinion of management, all adjustments
             are of a normal recurring nature. Operating results for the
             three-month and six-month periods ended June 30, 2002 are not
             necessarily indicative of the results that may be expected for
             future quarters or the year ending December 31, 2002.

             The audited financial statements at December 31, 2001, which are
             included in the Company's Annual Report on Form 10-KSB, should be
             read in conjunction with these condensed consolidated financial
             statements.

--------------------------------------------------------------------------------
NOTE 2.         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
--------------------------------------------------------------------------------

             Use of Estimates

             The preparation of financial statements in conformity with
             accounting principles generally accepted in the United States of
             America requires management to make estimates and assumptions that
             affect the reported amounts of assets and liabilities, and
             disclosure of contingent assets and liabilities at the date of the
             financial statements and the reported amounts of revenues and
             expenses during the respective reporting period. Actual results
             could differ from those estimates.

             The allowance for changes in contracts is an estimate established
             through reductions to sales while the allowance for doubtful
             accounts is an estimate established through charges to general and
             administrative expenses. Management's judgment in determining the
             adequacy of the allowances is based upon several factors which
             include, but are not limited to, analysis of subsequent changes to
             contracts, analysis of delinquent accounts, the nature and volume
             of the accounts, the payment histories of the accounts, and
             management's judgment with respect to current economic conditions.
             Given the nature of accounts receivable, it is reasonably possible
             the Company's estimate of the allowances will change in the near
             term.

             Reclassification

             Certain prior year amounts have been classified to conform to the
             current year presentation.

             Revenue and Cost Recognition

             Revenues from contracts are generally recognized on the
             percentage-of- completion method of accounting. Contracts may
             contain provisions for renegotiation in the event of cost overruns
             due to changes in the level and scope of work. Renegotiated amounts
             are included in revenue when earned and realization is assured.
             Provisions for losses to be incurred on contracts are recognized in
             full in the period in which it is determined that a loss will
             result from performance of the contractual arrangement.

                                       5
<PAGE>



-------------------------------------------------------------------------------
NOTE 2.         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
-------------------------------------------------------------------------------

             Direct costs include all direct costs related to contract
             performance. Selling, general and administrative costs are charged
             to expense as incurred. Changes in job performance and estimated
             profitability may result in revisions to costs and income, and are
             recognized in the period in which the revisions are determined. Due
             to the inherent uncertainties in estimating costs, it is at least
             reasonably possible that the estimates used will change in the near
             term and the change could be material.

             Included in accounts receivable are unbilled amounts, which
             represent revenue recognized in excess of amounts billed. Advance
             billings represent amounts billed in excess of revenue recognized.

             Net Earnings Per Share

             The Company applies Statement of Financial Accounting Standards No.
             128, "Earnings Per Share" (FAS 128) which requires dual
             presentation of net earnings per share: Basic and Diluted. Basic
             earnings per share is computed using the weighted average number of
             common shares outstanding during the period. Diluted earnings per
             share is computed using the weighted average number of common
             shares outstanding during the period adjusted for incremental
             shares attributed to outstanding options and warrants to purchase
             approximately 824,013, and 950,485 shares of common stock for the
             three month and six month periods ended June 30, 2002, and
             1,852,890 and 963,291 shares for the three and six months ended
             June 30, 2001, respectively; less the assumed repurchase of shares
             in accordance with the treasury stock method of approximately
             444,065 and 436,227 shares for the three and six-month periods
             ended June 30, 2002 and 963,291 and 684,483 shares for the three
             and six month periods ended June 30, 2001, respectively.

             On July 17, 2002, the Company announced a common stock buyback plan
             of up to 750,000 shares. As of August 6, 2002, the Company had
             purchased 106,300 shares in various open market purchases at an
             average price of approximately $9.41 per share, or a total
             expenditure of approximately $1,000,000. The Company may continue
             to purchase its shares, or may discontinue the buyback at any time
             depending on the selling price of common stock, the viability of
             potential acquisition targets, and the Company's cash flows from
             operations and on hand cash balances.

             New Accounting Pronouncements

             The Company adopted SFAS 142 effective January 1, 2002, as
             required. Annual goodwill amortization of approximately $135,000
             was discontinued. The Company is in the process of performing a
             transitional fair value based impairment test on its goodwill by,
             and if the fair value is less than the recorded value at January 1,
             2002, the impairment loss, if any, will be reflected as a
             cumulative effect of a change in accounting principle retroactive
             to the first quarter of 2002.

             In August 2001, the Financial Accounting Standards Board (FASB)
             issued Statement of Financial Accounting Standards (SFAS) No. 144,
             "Accounting for the Impairment or Disposal of Long-Lived Assets."
             SFAS No. 144 supersedes SFAS No. 121, "Accounting for the
             Impairment of Long-Lived Assets and for Long-Lived Assets to be
             Disposed Of." SFAS No. 144 retained substantially all of the
             requirements of SFAS No. 121 while resolving certain implementation
             issues. SFAS No. 144 is effective for fiscal years beginning after
             December 15, 2001. Management believes the impact of this
             pronouncement on its operations, if any, will not be material.


--------------------------------------------------------------------------------
NOTE 3.         SIGNIFICANT TRANSACTIONS
--------------------------------------------------------------------------------

             Our Acquisition of Anapharm

             On March 18, 2002, we acquired 100% of the capital stock of
             Anapharm, Inc. (Anapharm), which was the largest privately held
             Canadian provider of drug development services. Anapharm derives
             approximately 50% of its revenues from each of Phase I clinical
             trials and bioanalytical laboratory services. Anapharm also owns
             49% of Danapharm, Inc., an Ontario, Canada based corporation
             specializing in Phase III and IV clinical trials. All dollar
             references in this Report are in United States dollars.

             We acquired 100% of the issued and outstanding stock of Anapharm
             for approximately $26.8 million in cash and 167,375 shares of
             common which were valued at $3.3 million dollars plus transaction
             fees and costs. Anapharm executives, who were also Anapharm
             stockholders, received approximately 30% of the total consideration
             including all of the SFBC common stock. Additionally, key Anapharm
             employees received stock options to purchase 110,000 shares of SFBC
             common stock exercisable at $23.97 per share. The acquisition was
             accounted for as a purchase in accordance with SFAS 141 resulting
             in goodwill of approximately $15,324,586, which is attributable to
             the general reputation of the business and the collective
             experience of the management and employees. The results of
             operations of Anapharm from March 18, 2002 through June 30, 2002
             are included in the accompanying Condensed Consolidated Statement
             of Earnings for the three-month and six-month periods ended June
             30, 2002.

                                       6
<PAGE>

             Unaudited Pro Forma Results

             Unaudited pro forma results of operations after giving effect to
             certain adjustments resulting from the 2002 Anapharm acquisition
             were as follows for the periods ended June 30, 2002 and June 30,
             2001 as if the acquisition had occurred at the beginning of each
             period presented:
<TABLE>
<CAPTION>

                                      Three Months Ended June 30                 Six Months Ended June 30
                                  -------------------------------          -------------------------------------
                                        2002             2001                 2002            2001
                                        ----             ----                 ----            ----

<S>                               <C>              <C>                  <C>              <C>
             Net revenue          $   14,720,863   $   13,229,704       $   29,411,544   $   24,602,015
             Net earnings         $    1,355,038   $    1,681,194       $    3,273,257   $    2,991,213
             Earnings per share   $          .19   $          .30       $         .48    $          .53
             - basic
             Earnings per share   $          .18   $          .26       $         .44    $          .49
             - diluted
</TABLE>

             The pro forma data is provided for information purposes only and
             does not purport to be indicative of results that actually would
             have been obtained if the acquisition had been effected at the
             beginning of each period presented, or of those results which may
             be obtained in the future.

--------------------------------------------------------------------------------
NOTE 4.         GOODWILL AND INTANGIBLE ASSETS
--------------------------------------------------------------------------------

             In June 2001, the Financial Accounting Standards Board approved the
             issuance of SFAS 142, "Goodwill and Other Intangible Assets", which
             establishes new accounting and reporting requirements for goodwill
             and other intangible assets. The new standard requires that all
             intangible assets acquired that are obtained through contractual or
             legal right, or are capable of being separately sold, transferred,
             licensed, rented or exchanged must be recognized as an asset apart
             from goodwill. Goodwill and intangibles with indefinite lives are
             no longer amortized, but are subject to an annual assessment for
             impairment by applying a fair value based test.

             The Company applied the provisions of SFAS 142 beginning on January
             1, 2002 and is in the process of performing a transitional fair
             valued based impairment test on its goodwill and if the fair value
             is less than the recorded value at January 1, 2002, the impairment
             loss, if any, will be reflected as a cumulative effect of a change
             in accounting principle in the first quarter of 2002.

             As of June 30, 2002, the Company has total consolidated goodwill,
             net of accumulated amortization of $19,808,276, which includes
             $15,324,586 of goodwill related to the Anapharm acquisition on
             March 18, 2002.

             The assets acquires and liabilities assumed were recorded at
             estimated fair values as determined by the Company's management
             based on information currently available and on current assumptions
             as to future operations. The Company has obtained preliminary
             independent appraisals of the fair values of the acquired property
             plant and equipment, and identified intangible assets, and their
             remaining useful lives. Accordingly, the allocation of the purchase
             price is subject to revision, based on the final determination of
             appraised and other fair values.

             In connection with adopting SFAS 142, the Company also reassessed
             the useful lives and the classifications of its identifiable
             intangible assets and determined that they continue to be
             appropriate. The components of the Company's intangible assets
             subject to amortization are approximately as follows:
<TABLE>
<CAPTION>
                                                        June 30, 2002          December 31, 2001
                                                        -------------          -----------------
                                          Gross     Gross
                                          Average  Carrying   Accumulated     Carrying   Accumulated
                                           Life     Amount    Amortization     Amount    Amortization
                                        --------  ----------   ----------   ------------  ----------
                                          (Years)
<S>                                          <C>  <C>          <C>           <C>          <C>
             Methodologies                   4    $1,721,000   $ (163,000)   $  150,000   $  (11,000)
             Employment Agreement            5       590,000     (104,000)      590,000      (44,000)
             Subject Data-base               4       900,000      (66,000)           --           --
                                                  ----------   ----------    ----------   ----------
                                                  $3,211,000   $ (333,000)   $  740,000   $  (55,000)
</TABLE>


                                       7
<PAGE>

             Amortization expense for intangible assets during the three and
             six-month period ended June 30, 2002 were $209,875 and $277,875,
             respectively. The following table provides information regarding
             estimated amortization expense for each of the following years
             ended December 31:
<TABLE>
<CAPTION>
                                                                                                   (In thousands)
<S>            <C>                                                                                    <C>
               2002....................................................................               $ 685,244
               2003....................................................................                 825,571
               2004....................................................................                 825,571
               2005....................................................................                 694,738
               2006....................................................................                 142,625
</TABLE>

       The following table adjusts earnings and earnings per share for the
adoption of SFAS 142:
<TABLE>
<CAPTION>
                                                                            Three months ended,            Six months ended,
                                                                         2002              2001            2002           2001
                                                                         ----              ----             ----          ----
<S>                                                                 <C>               <C>             <C>             <C>
        Reported net earnings ...................................   $   1,355,038     $     867,964   $   2,684,843   $   1,628,787
        Add: Goodwill amortization, net of tax ..................              --     $       4,700              --   $      20,600
          Adjusted net earnings .................................   $   1,355,038     $     872,644   $   2,684,843   $   1,649,387
     Basic earnings per share:
        Reported net earnings ...................................   $        0.19     $        0.24   $        0.39   $        0.45
        Add: Goodwill amortization, net of tax ..................              --     $          --              --   $        0.01
          Adjusted net earnings .................................   $        0.19     $        0.24   $        0.39   $        0.46
     Diluted earnings per share:
        Reported net earnings ...................................   $        0.18     $        0.19   $        0.36   $        0.40
        Add: Goodwill amortization, net of tax ..................              --     $          --              --   $          --
          Adjusted net earnings .................................   $        0.18     $        0.19   $        0.36   $       .0.40
</TABLE>


ITEM 2.      MANAGEMENT'S DISCUSSION AND ANALYSIS OF INTERIM FINANCIAL
             CONDITION AND RESULTS OF OPERATIONS

             As used in the quarterly report on Form 10-QSB, "we", "our", "us",
             the "Company" and "SFBC" refer to SFBC International Inc and its
             subsidiaries unless the context otherwise requires.

             The following discussion of our financial condition and results of
             operations should be read together with the financial statements
             and related notes included in this Report. This discussion contains
             forward-looking statements that involve risks and uncertainties.
             Our actual results may differ materially from those anticipated in
             those forward-looking statements as a result of certain factors,
             including, but not limited to, those contained in the discussion on
             forward-looking statements that follows this section.

             Overview

             We are a provider of specialized drug development services to the
             pharmaceutical and biotechnology industries. We specialize in
             recruiting for and conducting Phase I and Phase II clinical trials
             involving participants from special populations. Our clients
             include the largest pharmaceutical manufacturers in the world,
             biotechnology companies and other drug development services
             companies which are also our competitors. Our principal operation
             is located in Miami, Florida and is, we believe, the largest Phase
             I and Phase II clinical trials facility in the United States. In
             addition, we provide Phase III clinical trials management services
             in targeted therapeutic areas and also provide our clients with
             analytical laboratory services. Our services help reduce the amount
             of time and expense associated with clinical trials and enable our
             clients to bring new drugs to the market faster.

             Our revenues consist primarily of fees earned under contracts with
             pharmaceutical and biotechnology company clients. In most cases, a
             portion of our contract fee is due upon signing of the contract,
             and the balance of the contract fee is generally paid in
             installments over the duration of the clinical trial.

             Revenues for contracts are recognized on a percentage of completion
             basis as we conduct each stage of a clinical trial. Our contracts
             generally range in duration from several weeks to in excess of one
             year.


                                       8
<PAGE>

             With the acquisition of Anapharm we now have a total of more than
             750 beds and 12 discrete units. Our facilities are located in the
             United States in Miami and Ft. Myers, Florida; Charlotte, North
             Carolina; Philadelphia, Pennsylvania; and in Canada in Montreal and
             Quebec City. These sites include state-of-the-art-bioanalytical
             laboratories and a clinical laboratory that we opened in December
             of 2001. We specialize in geriatrics, pediatrics, post-menopausal
             women, cardiac disease, diabetes, kidney disease, ophthalmology,
             HIV and dermatology which include some of the most challenging
             special populations. In addition to our core Phase I and Phase II
             testing for both branded and generic pharmaceutical and
             biotechnology companies, SFBC provides Phase III and Phase IV trial
             management services. We also offer central laboratory and
             bioanalytical services.

             History

             SFBC was organized as a Florida corporation in 1984 and
             reincorporated in Delaware in 1999.

             In March 2000, we acquired Pharmaceutical Development Associates,
             Inc., a Phase III clinical trials management services company
             located in Charlotte, North Carolina. Pharmaceutical Development
             Associates specialized in several therapeutic areas including
             ophthalmology and dermatology. This business comprises our Phase
             III operations, which we believe to be among the most active
             providers of ophthalmology drug studies and a leading provider of
             dermatology drug studies.

             In February 2001, we acquired Ft. Myers, Florida based LeeCoast
             Research Center, Inc. a Phase I through Phase IV clinical trials
             operation, which specializes in dermatology and vasoconstrictor
             studies. In August 2001, we acquired Keystone Analytical
             Laboratories Inc., an analytical testing and analysis laboratory
             located in Philadelphia, Pennsylvania.

             In March 2002, we acquired Anapharm, Inc. the largest privately
             held Canadian provider of drug development services. (See Note 3 to
             the Condensed Consolidated Financial Statements, "Our Acquisition
             of Anapharm").

             Results of Operations

             During the first six months ended June 30, 2001 we had operations
             in Miami and Charlotte and for four and one-half months in Ft.
             Myers. In contrast, during the same six months during 2002 we had
             operations in Miami, Charlotte, Ft. Myers and Philadelphia and for
             three and one-half months at Anapharm. All dollar references used
             in this report are in United States dollars.

             Three and Six Months Ended June 30, 2002 Compared to Three and Six
             Months Ended June 30, 2001.
             -------------------------------------------------------------------

             Net Revenue
             -----------

             Net revenue increased from $7,571,122 to $14,720,863 for the three
             months ended June 30, 2002 and from $14,153,099 to $24,303,419 for
             the six months ended June 30, 2002, an increase of 94.4% and 71.7%
             respectively from the corresponding periods in the prior year. The
             increase for both the three and six month periods is primarily
             attributable to the inclusion in revenue of six months of
             operations at SFBC Analytical and three and one-half months of
             operations at Anapharm for the period ended June 30, 2002 compared
             to zero for the same three and six month periods ended June 30,
             2001.This was partially offset by a decrease in revenues at our
             Miami facility, on a comparable basis. The net revenues in Miami
             for the three-month period ended June 30, 2002 were impacted by the
             postponement of approximately $2,000,000 in contract revenue.

             On a proforma basis, if the Company had owned all of its
             subsidiaries as of January 1, 2001, net revenue for the six-month
             period ended June 30, 2002 increased approximately 9.8% over same
             six-month period ended June 30, 2001.

             Gross Profit
             ------------

             Gross profit increased from $3,259,749 to $6,266,833 for the three
             months ended June 30, 2002 and from $6,027,010 to $10,987,645 for
             the six months ended June 30, 2002, an increase of 92.2% and 82.3%
             respectively from the corresponding periods in the prior year. As a
             percentage of net revenue, gross profit decreased from 43.1 % to
             42.6 % for the three months ended June 30, 2002 and increased from
             42.6% to 45.2% for the six months ended June 30, 2002 as compared
             to the corresponding periods in the prior year. The decrease for
             the three month period ended June 30, 2002 compared to the same
             period in 2001 is primarily attributable to the inclusion of
             Anapharm gross profits percentages which were slightly below our
             historical level prior to the Anapharm acquisition, the
             postponement of approximately $2,000,000 in higher margin Phase I
             Miami contracts, and an increase in lower margin Phase III business
             as a ratio of overall business, offset by the inclusion of higher
             margin bioanalytical business at SFBC Analytical in Philadelphia
             which was acquired in August 2001.


                                       9
<PAGE>

             The increase in gross profit as a percentage of net revenue for the
             six months ended June 30, 2002 compared to the same period in 2001
             is primarily attributable to the inclusion of gross margins from at
             SFBC Analytical which are typically higher than margins in our
             clinical trials business.

             On a going forward basis the mix of our contracts, will vary from
             quarter-to-quarter. This will impact our future profit margins and
             gross profit comparisons to historical levels. . For the remaining
             six months of 2002 we anticipate that the gross margin will be
             approximately 45%.

             Selling, General and Administrative Expenses
             --------------------------------------------

             Selling, general and administrative expenses (S, G&A) increased
             from $1,935,081 to $4,766,890 for the three months ended June
             30,2002 and from $3,547,128 to $7,597,955 for the six months ended
             June 30, 2002, an increase of 146.3% and 114.2%, respectively, over
             the same periods in the prior year. As a percentage of net revenue,
             our S, G&A expenses increased from 25.6% to 32.4% for the three
             months ended June 30, 2002 and from 25.1% to 31.3% for the six
             months ended June 30, 2002 as compared to the corresponding periods
             in the prior year.

             The increase for both periods is primarily due to the expansion of
             our business, our increased marketing efforts and the inclusion of
             Anapharm's S, G&A expenses. Additionally during the three months
             ended June 30, 2002, the Company incurred $90,000 of one-time
             acquisition related expenses and a foreign exchange loss of
             $145,000 at Anapharm due to the decline of the US dollar against
             the Canadian dollar on several long-term contracts Anapharm had
             entered into. These amounts have been included in S, G&A expenses.
             The Company anticipates that it will not incur any significant
             additional foreign exchange losses for the remainder of the current
             year, however, there can be no assurances.

             As a result of the acquisition of Anapharm on March 18, 2002, the
             Company expects its S, G &A expenses as a percentage of revenue to
             remain at, or near current levels. This is primarily attributable
             to the nature of Anapharm's business where it employs a higher
             number of research and development employees and incurs higher S,
             G&A expenses as a percentage of revenues than our United States
             subsidiaries. In Canada the government subsidizes a large portion
             of these additional expenses through issuing Anapharm tax credits.
             Under United States GAAP these credits are not credited against S,
             G&A expenses; instead they are credited against income tax expense.
             The net impact is that our net income is not changed by this
             accounting treatment while S, G&A expenses as a percentage of
             revenues will be permanently higher and our effective tax rate will
             be permanently lower than in the past.

             Net Income
             ----------

             Net income increased from $867,954 to $1,355,038 for the three
             months ended June 30, 2002 and from $1,628,787 to $2,684,845 for
             the six months ended June 30, 2002, an increase of 56.1% and 64.8%
             respectively over the same periods in the prior year. On a fully
             diluted basis, our earnings per share decreased from $.19 to $.18
             for the three-month period ended June 30, 2002 and from $.40 to
             $.36 for the six-month period ended June 30, 2002 as compared to
             the corresponding periods in the prior year. The weighted average
             number of shares outstanding used in computing earnings per share
             on a fully diluted basis increased from 4,489,414 to 7,459,428 for
             the three month period ended June 30, 2002 and from 4,116,236 to
             7,404,560 for the six month period ended June 30, 2002 as compared
             to the corresponding periods in the prior year. The increase in the
             number of shares resulted primarily from the issuance of 2,000,000
             shares of common stock in connection with our secondary offering in
             December 2001, the exercise of 709,321 warrants in August 2001, the
             issuance of approximately 167,000 shares in connection with the
             Anapharm acquisition, and the exercise of approximately 300,000
             warrants and options between April 2002 and May 2002 and an
             increase in the Company's share price resulting in an increase in
             the dilutive effect from the outstanding stock options to be
             included as common stock equivalents using the treasury method.

             On July 17, 2002, the Company announced a common stock buyback plan
             of up to 750,000 shares. As of August 6, 2002, the Company had
             purchased 106,300 shares in various open market purchases at an
             average price of approximately $9.41 per share, or a total
             expenditure of approximately $1,000,000. The Company may continue
             to purchase its shares, or may discontinue the buyback at any time
             depending on the selling price of common stock, the viability of
             potential acquisition targets, and the Company's cash flows from
             operations and on hand cash balances.

             The Company's effective tax rate for the three-month period ended
             June 30, 2002 was 11.1% compared to 38.2% for the same period in
             2001. This decrease is primarily attributable to Anapharm's strong
             operating results as a ratio of overall consolidated net income and
             Anapharm's significantly lower tax rate, compared to the
             non-inclusion of Anapharm during the same period in 2001. For the
             six months ended June 30, 2002, the Company's effective tax rate
             was 24.8% compared to 38.4% for the same period in 2001. The
             decrease is attributable to the inclusion of Anapharm operations
             for the period March 18, 2002 through June 30, 2002 compared to the
             non-inclusion of Anapharm during the same period in 2001. As
             described throughout this report, Anapharm receives significant
             certain non-cash tax credits from the government of Canada for
             incurring research and development expenses. These credits lower
             the Company's effective tax rate. The Company expects the nature of
             Anapharm's business and the generation of significant tax credits
             to continue, however, there can be no assurance on the amount of
             these credits on a quarterly or annual basis.


                                       10
<PAGE>

             On a going forward basis, the Company expects its effective tax
             rate to be between 22.0%-26.0% as compared to the historical tax
             rate of 35.0% to 38.5% (based upon earnings in the United States
             only), The effective tax rate will be dependent on the amount of
             the credits Anapharm receives and Anapharm's relative contribution
             to consolidated operating net income.

             In April 2002 SFBC's chairman and SFBC's chief executive officer
             agreed to a modification of their employment agreements. Under the
             previous terms of their employment agreements, the chairman and
             chief executive officer were entitled to annual bonuses of 5% and
             3% of pre-tax income, respectively, which were capped at one times
             their base salary. Under the new terms of their agreements, these
             officers agreed to a 50% reduction of their bonus percentages to 2
             1/2% and 1 1/2%, respectively, capped at one times salary
             retroactive to January 1, 2002 and waived their combined bonus
             earned of approximately $82,000 for the three months ended March
             31, 2002. In return for reducing their future bonus percentages,
             the board of directors of SFBC increased the chairman's salary and
             the chief executive's salary by $25,000 each. Additionally, in
             April 2002 each of these officers were awarded 56,200 stock options
             at a strike price of $19.13. The Company properly accrued these
             bonuses in accordance with these employment agreements for the
             three month period ended June 30, 2002.

             Liquidity and Capital Resources
             -------------------------------

             For the six months ended June 30, 2002 net cash used in operating
             activities was $1,702,890 compared to $1,038,356 provided by
             operating activities for the corresponding period in 2001. The
             decrease is attributable to income tax payments and an increase in
             accounts receivable, offset by an increase in net operations.

             For 2002, net cash used in investing activities was $23,146,227
             compared to $1,374,505 of net cash used in investing activities
             during the same period in 2001. The change is primarily due to
             approximately $22,000,000 of net cash used to purchase Anapharm.

             In the six months ended June 30, 2002, net cash provided in
             financing activities was $1,441,911 compared to cash of $363,265
             used in financing activities for the same period in 2001. The
             increase is primarily attributable to proceeds from the exercise of
             stock options.

             Working capital was $27,116,380 at June 30, 2002, a decrease of
             $17,475,781 from December 31, 2001. This decrease is attributable
             the use of $22,047,577 of net cash to purchase Anapharm.

             On December 18, 2001 we sold 2,000,000 shares in a secondary
             offering and received $29,590,201 of net proceeds. On March 18,
             2002 we used approximately $26,800,000 of our cash balances to
             purchase Anapharm. At the time of acquisition Anapharm had
             approximately $4,600,000 of cash on hand. As part of its plan to
             enhance its business potential, Anapharm intends to acquire at
             least $2,000,000 of capital equipment. The Company believes that
             Anapharm's cash flow from operations going forward will be
             sufficient to fund these capital requirements.

             At August 13, 2002 we had approximately $14,265,000 of cash on
             hand. Based upon our cash balances and positive cash flows from
             operations, we believe we have more than enough working capital to
             meet our operational needs for the next 12 months. We are in the
             process of finalizing a $10,000,000 line of credit to enable us to
             complete future acquisitions if our on hand cash balances are not
             sufficient to fund the potential acquisition. Except for the
             possibility of issuing stock related to a potential accretive
             acquisition, should one arise, we do not anticipate selling any of
             our common stock during 2002. This does not include the issuance of
             shares relating to the exercise of any outstanding stock options or
             warrants. From April 1, 2002 through May 6, 2002 the number of our
             shares outstanding increased from approximately 6,858,000 to
             7,140,000 shares due to the exercise of stock options and warrants.

             On July 17, 2002, the Company announced a common stock buyback plan
             of up to 750,000 shares. As of August 6, 2002, the Company had
             purchased 106,300 shares in various open market purchases at an
             average price of approximately $9.41 per share, or a total
             expenditure of approximately $1,000,000. The Company may continue
             to purchase its shares, or may discontinue the buyback at any time
             depending on the selling price of common stock, the viability of
             potential acquisition targets, and the Company's cash flows from
             operations and on hand cash balances.


                                       11
<PAGE>

             Other Matters
             -------------

             In December 2001 we made a loan to our executive-vice president in
             the amount of $62,500 and in April 2002 an additional $215,000. In
             May 2002 these loans were repaid in full with interest. In June
             2002, our Audit Committee extended the due date on the $97,226 loan
             we made to Dr. Lisa Krinsky in 1999, from August 1, 2002 to August
             1, 2003.

             In August 2001, the Financial Accounting Standards Board (FASB)
             issued Statement of Financial Accounting Standards (SFAS) No. 144,
             "Accounting for the Impairment or Disposal of Long-Lived Assets."
             SFAS No. 144 supersedes SFAS No. 121, "Accounting for the
             Impairment of Long-Lived Assets and for Long-Lived Assets to be
             Disposed Of." SFAS No. 144 retained substantially all of the
             requirements of SFAS No. 121 while resolving certain implementation
             issues. SFAS No. 144 is effective for fiscal years beginning after
             December 15, 2001. Management believes the impact of this
             pronouncement on its operations, if any, will not be material.

             Forward-Looking Statements
             --------------------------

             The statements in this Report relating to our expectations about
             our future gross margins, S,G&A expense percentages and tax rates
             and credits, the reduction of significant foreign exchange losses
             at Anapharm, the possibility of future dilution, the adequacy of
             our working capital, finalizing a new credit facility, new capital
             expenditures and future acquisitions are forward-looking statements
             within the meaning of the Private Securities Litigation Reform Act
             of 1995 (the "Act"). Additionally, words such as "expects",
             "anticipates", "intends", "believes", "will" and similar words are
             used to identify forward-looking statements within the meaning of
             the Act.

             The results anticipated by any or all of these forward-looking
             statements might not occur. Important factors, uncertainties and
             risks that may cause actual results to differ materially from these
             forward-looking statements include (1) an unanticipated decision to
             make an acquisition of a substantially larger competitor, which
             would require us to re-allocate our intended uses of our cash
             resources; (2) our ability to successfully implement our plans for
             operational and geographical expansion; (3) our ability to
             successfully achieve and manage the technical requirements of
             specialized clinical trial services, while maintaining compliance
             with applicable rules and regulations; (4) our ability to compete
             nationally in attracting pharmaceutical companies in order to
             develop additional business; (5) our continued ability to recruit
             participants for clinical studies; (6) the economic climate
             nationally and internationally as it affects drug development
             operations, (7) our ability to integrate and absorb any future
             acquisitions into our current operational structure, (8) the
             changing mix of, and the amount contracts and laboratory services
             offered, (9) our ability to continue to generate tax credits at
             Anapharm to lower the effective tax rate and (10) our ability to
             finalize an acquisition line of credit on favorable terms with a
             financial institution to fund potential acquisitions.

             We undertake no obligation to publicly update or revise any
             forward-looking statements, whether as the result of new
             information, future events or otherwise. For more information
             regarding some of the ongoing risks and uncertainties of our
             business, see our other filings with the Securities and Exchange
             Commission.
<PAGE>

                           PART II - OTHER INFORMATION


ITEM 1. Legal Proceedings

             In July 2002 the Company filed suit against Eisai, Inc. in the
             Circuit Court for the Eleventh Judicial Circuit of Florida. The
             suit seeks the payment of Two Hundred and Two Thousand Four Hundred
             Seventy Five Dollars ($202,475.00) together with interest which
             Eisai, Inc. failed to pay in accordance with a contract for
             services. The Company provided the services required pursuant to
             the contract under the supervision of the defendant and in
             accordance with the protocols supplied. Eisai, Inc. has not yet
             filed an Answer and has requested and received leave for an
             extension of time to file same.


ITEM 2. Changes in Securities

              During the six months ended June 30, 2002, we issued shares of our
              common stock to the following individuals and corporation upon
              exercise of options or warrants which were not covered by an
              effective registration statement but were exempt under Section
              4(2) of the Securities Act of 1933:


                                       12
<PAGE>
<TABLE>
<CAPTION>
                                                                              Number of
                   Date                            Name                        Shares                Consideration
                   ----                            ----                        ------                -------------
<S>           <C>                                  <C>                          <C>            <C>
              February 1, 2002                     Robert Dudley                 2,050         Cashless Warrant Exercise

              March 8, 2002               George L. May and Linda J. May         1,174         Cashless Warrant Exercise

              March 11, 2002                  Keith C. Carini, D.D.S.            1,211         Cashless Warrant Exercise

              March 18, 2002                 Getstion Marc Lebel, Inc.          48,352         Common Stock of Anapharm, Inc.

              March 18, 2002                        Marc Lebel                  41,750         Common Stock of Anapharm, Inc.

              March 18, 2002                      Francois Vallee               56,335         Common Stock of Anapharm, Inc.

              March 18, 2002                      Guylaine Perron                3,590         Common Stock of Anapharm, Inc.

              March 18, 2002                        Eric Masson                  3,590         Common Stock of Anapharm, Inc.

              March 18, 2002                      Stephanie Marin                2,991         Common Stock of Anapharm, Inc.

              March 18, 2002                 Johane Boucher Champagne            5,983         Common Stock of Anapharm, Inc.

              March 18, 2002                        Denis Hache                  1,196         Common Stock of Anapharm, Inc.

              March 18, 2002                  Nicolas Stephen D'Ulise            1,196         Common Stock of Anapharm, Inc.

              March 18, 2002                       Jean Couture                  1,196         Common Stock of Anapharm, Inc.

              March 19, 2002                  H.D. Brous & Co., Inc.            15,861         Cashless Warrant Exercise

              April 1, 2002                   H.D. Brous & Co., Inc.            16,667         Cashless Warrant Exercise

              April 18, 2002                     David M. Kushner                3,906         $9.60 Warrant Exercise

              April 19, 2002                       Joanne B. May                 2,715         Cashless Warrant Exercise

              May 9, 2002                         Joseph E. Webb                 5,672         Cashless Warrant Exercise

              May 17, 2002                          Jerry Nash                   2,611         Cashless Warrant Exercise

              June 6, 2002             Harold T. George and Ruth B. George,      3,599         Cashless Warrant Exercise
                                                     TTEE UAD

              June 6, 2002                          Jerry Frost                  2,505         CashlessWarrant Exercise

              June 6, 2002                      Robert P. Bisaillon              1,896         Cashless Warrant Exercise

              June 11, 2002                       Carl J. Wallace                1,849         Cashless Warrant Exercise

              June 13, 2002                      Frank L. Jenkins                1,532         Cashless Warrant Exercise

              June 13, 2002                       Dennis D. Glass                3,727         Cashless Warrant Exercise

              June 18, 2002               Harold and Marilyn F. Chalmers        16,473         Cashless Warrant Exercise

              June 18, 2002                         Leo Watkins                  3,856         Cashless Warrant Exercise
</TABLE>

              The warrant holders acquired their warrants when the Company
              converted notes previously issued to the warrant holders.

                                       13
<PAGE>

             The March 18, 2002 common stock transfers were consideration for
             the Company's purchase of the common stock of Anapharm, Inc.

ITEM 3.  Defaults Upon Senior Securities

              Not applicable.


ITEM 4.  Submission of Matters to a Vote of Security Holders

             On June 24, 2002, we held our annual meeting of stockholders. The
             stockholders approved the following matters:

             1.   The election of the five nominees to serve on the
                  Board of Directors for a term of one year, or until
                  their respective successors are duly elected and
                  qualified.

                  Directors                    For                     Withheld
                  --------------------------------------------------------------
                  Lisa Krinsky, MD           5,314,978                  310,749
                  Arnold Hantman             5,314,063                  311,664
                  Jack Levine                5,502,909                  122,818
                  David Lucking              5,503,909                  121,818
                  Dr. Leonard Weinstein      5,406,419                  219,308

                  The five nominees represent our entire board of directors.
                  There were no abstentions or broker non-votes.

             2.   The approval of an amendment to SFBC's Second Amended and
                  Restated 1999 Stock Option Plan increasing the number of
                  options by 500,000 to a total of 1,700,000 available for
                  grant. In this matter, there were 2,621,760 votes in favor,
                  934,036 votes against, 22,611 abstentions, and 2,047,320
                  broker non-votes which vote was sufficient under Delaware law.

             3.   The approval and ratification of Grant Thornton LLP as SFBC's
                  independent auditors for 2002. In this matter, there were
                  5,529,940 votes in favor, 83,861 votes against, and 83,861
                  abstentions with no broker non-votes.

ITEM 5.  Other Information

             Not applicable.

ITEM 6.  Exhibits and Reports on Form 8-K.

             (a)  Exhibit Index

             Exhibit
             Number       Description
             ------       -----------

              2.1         Share Purchase Agreement (Anapharm)(1)
             10.1         Employment Agreement of Dr. Marc Lebel (1)
             10.2         Employment Agreement of David Natan (1)
             10.3         Employment Agreement of Thomas J. Pillsworth, Jr. (1)
             10.4         Amendment to Employment Agreement of Dr. Allan Xu (2)
             10.5         Waiver of Bonus of Lisa Krinsky, M.D. (2)
             10.6         Waiver of Bonus of Arnold Hantman (2)
                                       14
<PAGE>

                 (1)  Contained in Form 10-KSB for year ended December 31, 2001.

                 (2)  Contained in Form 10-QSB for quarter ended March 31, 2002.

             (b)  Reports on Form 8-K.

             Four reports on Form 8-K were filed during the quarter ended June
             30, 2002. The first report was filed on March 18, 2002 to report
             the acquisition Anapharm by SFBC. This report was amended on June
             3, 2002 to include the required financial statements. This report
             was further amended on June 4, 2002 to amend certain pro forma
             financial statements of Anapharm. The fourth report was filed on
             July 19, 2002 to update prior disclosure.


                                       15
<PAGE>


                                   SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the
registrant caused this report to be signed on its behalf on August 14, 2002 by
the undersigned, thereunto duly authorized.

                                       SFBC International, Inc.


                                        /s/ Arnold Hantman
                                       ---------------------------------------
                                       Arnold Hantman, Chief Executive Officer

                                       /s/ David Natan
                                       ---------------------------------------
                                       David Natan, Chief Financial Officer and
                                       Principal Accounting Officer